Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRIPositive

AI Analysis

Summary

Accord BioPharma launched FILKRI (filgrastim-laha), a long-acting G-CSF option with a permanent Q-code for standardized billing and reimbursement across care settings.

Outcome Details

Product launch of FILKRI with permanent Q-code for billing and reimbursement standardization

Importance:5/10

Sentiment:

0.60

product launchoncologyG-CSFreimbursementspecialty pharma

Related Companies

$DFPH

Read the original article

Published by PR Newswire Biotech on October 12, 2026 12:05 PM

Read Original